Fig. 4: Intravenous injection of BMSCs ameliorates immune and hematopoietic function of dKO mice.

A Survival curves of mice after treatment of BMSCs (10⁶ BMSCs dissolved in normal saline per mouse, n = 12). B, C Body weight change of mice after treatment of BMSCs (n = 6–12 at each time point). D Representative pictures of 1 to 4-month-old male control and dKO mice subjected to BMSCs. E Serum TNF-α and IL-1β concentrations in male control and dKO mice 2 months after subjected to BMSCs or 1 month after subjected to corresponding vehicle (n = 6). F Representative pictures of organs from male control and dKO mice subjected to BMSCs or corresponding vehicle. G Whole bone marrow cells of the tibia or femur from male control and dKO mice subjected to BMSCs or corresponding vehicle. H Tail bleeding time measured in male control and dKO mice subjected to BMSCs or corresponding vehicle (n = 6). I–M Routine blood examination of male control and dKO mice subjected to BMSCs or corresponding vehicle (n = 6). N–V FACS analysis of bone marrow cells in male control and dKO mice subjected to BMSCs or corresponding vehicle (n = 6). Data are mean ± SD of 3 independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.